Videos

  Clinical Conversations by Experts View all

PCF 2021 Videos

Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer

PSMA Academy Videos

Prostate cancer genomic classifier Videos

Practical Aspects of Radioligand Therapy in the Clinic Videos

Latest Videos

Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis
Mucosal Differences in The Bladder - Molly Ingersoll
Translational Research in Bladder Cancer, A BCAN Young Investigator - Phillip Abbosh
Imaging Prostate Cancer with F18 Fluciclovine PET - Neha Maithel & Isis Gayed
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
Resourcing the Patient and Caregivers Prostate Cancer Journey and The Prostate Cancer Foundation - Kneeland Youngblood
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor
Accelerating Research and Development to Save Lives - Esther Krofah
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
How I Treat Low-Risk Upper Tract Urothelial Carcinoma - Katie Murray
Urologists, You’ll Never Walk Alone! - Gianluca Giannarini
Cabazitaxel as a Third-Line Treatment After Docetaxel and an Androgen Receptor Targeting Agent in mCRPC Patients – Alicia Morgans
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano

A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer Videos

Featured Videos

Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
PSMA Imaging - Is Conventional Imaging Obsolete - Steven Rowe
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
Urogynecology Controversies: Female Pelvic Medicine and Reconstructive Surgery - Briana Walton
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Understanding Physiological PSMA Biodistribution - Jeremie Calais
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber
Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus
Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra
How I Use Jelmyto™ - Karim Chamie
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen
Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
Survivorship in Testicular Cancer - Mary Dunn
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Facing Pelvic Pain - Elise De
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope
Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
ESMO 2020 Expert Clinical Conversation on Prostate Cancer - Oliver Sartor
The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer - Steve Poggi
A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
In Pursuit of Patient-Centered Care - Karen Knudsen
Making Your Treatment Decision - Prostate Cancer Patient Interview with Andy Schwartz
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
Genetic Counseling in Prostate Cancer - Brittany Szymaniak
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
Clinical Trials: Another Treatment Option for Patients - Tom Farrington
Radium-223 in Clinical Practice - Phillip J. Koo
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Challenges in the Diagnosis and Treatment of UTUC - Peter Black
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
Immunotherapy Across Genitourinary Malignancies - James Gulley
Optimizing ADT in Prostate Cancer Patients - Tom Keane
Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
CARMENA: Practice Changing Strategies for Kidney Cancer
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
Nocturia in the Aging Patient, Assessment and Treatment- Susann Varano
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
Clinical Implications of the Abi Race Study: Interview with Dan George
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans
New Concepts in ADT- Thomas Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
Defining Bladder Health - Ariana Smith
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin
email news signup